SuviCa, CU Boulder, and CU Anschutz Announce Positive FDA Pre-IND Feedback for SVC112 Program in Advanced Solid Tumors

SuviCa, Inc., along with the University of Colorado Boulder and the University of Colorado Anschutz, today announced the successful completion of a Type B Pre-Investigational New Drug (pre-IND) interaction with the U.S. Food and Drug Administration (FDA) for SVC112, the company’s first-in-class protein synthesis inhibitor being developed for the treatment of advanced and metastatic solid tumors.